试验观察 - 双特异性T细胞参与剂和更高阶的多特异性免疫疗法
Enfu Xue1,2, Xiaolian Deng1,2, Flora Doffe1,2
1Université Paris Cité, Sorbonne Université, Inserm, Centre de Recherche des Cordeliers, Équipe labellisée par la Ligue contre le cancer, Institut Universitaire de France, Paris, France.
Oncoimmunology
|February 17, 2026
概括
双特异性T细胞参与剂 (TCE) 正在推进癌症免疫疗法,在血液癌症中表现出成功,但在固体瘤中面临挑战. 目前正在进行的研究重点是优化TCE,以实现更广泛的精确癌症治疗.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 癌症免疫疗法已成为癌症治疗的基石.
- 双特异性T细胞参与剂 (TCE) 和多特异性免疫疗法代表了精确免疫调节的先进策略.
- 这些工程抗体将免疫细胞重定向到向癌细胞,启动抗瘤反应.
研究的目的:
- 审查TCE和多种特异性免疫参与平台的近期临床前进展.
- 分析这些免疫疗法的当前临床试验数据.
- 讨论免疫参与者发展的关键因素,包括药理动力学,安全性,耐药性和制造.
主要方法:
- 对TCE和多种特异性免疫参与剂的临床前研究的文献综述.
- 分析已发表的临床试验数据.
- 检查免疫参与平台的关键开发考虑因素.
主要成果:
- 在血液性恶性瘤中,TCEs已经证明了显著的临床成功.
- 在固体瘤中实现可比的疗效仍然存在挑战.
- 设计和优化的进步正在提高这些工程抗体的多功能性.
结论:
- 免疫细胞重定向免疫疗法,特别是TCE,在精确癌症治疗中越来越多的多功能工具.
- 进一步开发对于克服固体瘤的局限性和扩大应用至关重要.
- 这些疗法将在未来的癌症治疗中发挥关键作用.
相关概念视频
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
T Cell Activation and Clonal Selection
16.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
16.4K


